MOUD Buprenorphine Subli denied as duplicate or overlapping therapy by Aetna?

Aetna's specific coverage criteria for moud buprenorphine subli are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Aetna Issues Duplicate-Therapy Denials for Buprenorphine (Sublingual)

Sublingual buprenorphine is a medication for opioid use disorder (MOUD) — a federally recognized, guideline-supported treatment. A duplicate-therapy denial means Aetna's system detected that another opioid partial agonist, another buprenorphine product (e.g., an implantable or injectable formulation), or another MOUD agent is already on file as active for the same patient. In most cases, this is either a claims-system artifact (an old prescription that was not closed out) or a legitimate clinical situation where the prescriber has transitioned formulations and both appear active simultaneously.

## Why This Denial Is Appealable

Duplicate-therapy flags are administrative in nature and are among the most straightforward denials to resolve. If the "duplicate" is a prior formulation that has been discontinued, the fix is a prescriber attestation confirming discontinuation and a request to clear the prior authorization. If the clinical situation genuinely involves co-prescribing (which is atypical but occasionally appropriate under specialist guidance), your prescriber can document the clinical rationale. Aetna's coverage policies for MOUD are also subject to the federal Mental Health Parity and Addiction Equity Act (MHPAEA), which prohibits imposing more restrictive utilization management on substance use disorder treatment than on comparable medical or surgical benefits.

## Your Federal Appeal Rights

• Internal appeal (ERISA §503 / ACA §2719): File within the deadline on the denial notice. MOUD denials are adverse benefit determinations entitled to full-and-fair review.
• MHPAEA parity argument: In your appeal, note that Aetna must apply duplicate-therapy criteria to SUD medications no more restrictively than to comparable medical treatments.
• External review (ACA §2719): After exhausting internal channels, an independent external reviewer can issue a binding decision. The window is approximately 4 months from final internal denial.
• Expedited review: Buprenorphine is an essential medication for OUD; if interruption poses a health risk, request expedited review with a 72-hour turnaround.

## Documentation to Gather

1. Current prescription list — a complete, dated medication list from your prescriber showing what is currently active and what has been discontinued. 2. Discontinuation confirmation — if the "duplicate" was a prior formulation, a prescriber note or letter confirming it was stopped and the date. 3. Prescriber rationale letter — explaining the treatment plan, the role of sublingual buprenorphine specifically, and why no true therapeutic duplication exists. 4. Prior authorization records — copies of any active or recently expired PAs to help Aetna reconcile its records.

## Criteria-Mapping Structure

Obtain Aetna's duplicate-therapy policy language from the denial letter or their provider portal. Identify exactly which "duplicate" agent triggered the flag. Your appeal should address that specific agent: document its status (discontinued, different formulation, different indication) and provide the prescriber's letter confirming the clinical picture. A clean, brief appeal with those two documents typically resolves this denial type at the internal stage.